Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Imidapril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 13/20 | 0.98 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imidapril SCHEMBL28101054 | 1.00 | ACE (0.98) | ACELMNAABCB11MEN1KMT2A | |
| Imidapril SCHEMBL7294155 | 1.00 | ACE (0.98) | ACELMNAABCB11MEN1KMT2A | |
| Imidapril SCHEMBL34098 | 0.99 | ACE (1.00) | ACELMNAABCB11MEN1KMT2A | |
| Imidapril SCHEMBL3193644 | 0.99 | ACE (1.00) | ACELMNAABCB11MEN1KMT2A | |
| Imidapril SCHEMBL6516062 | 0.99 | ACE (1.00) | ACELMNAABCB11MEN1KMT2A | |
| Imidapril SCHEMBL7354516 | 0.99 | ACE (1.00) | ACELMNAABCB11MEN1KMT2A | |
| Imidapril SCHEMBL12894585 | 0.99 | ACE (1.00) | ACELMNAABCB11MEN1KMT2A | |
| Imidapril SCHEMBL11014327 | 0.99 | ACE (1.00) | ACELMNAABCB11MEN1KMT2A | |
| Imidapril SCHEMBL22492310 | 0.99 | ACE (1.00) | ACELMNAABCB11MEN1KMT2A | |
| Imidapril SCHEMBL34099 | 0.99 | ACE (1.00) | ACELMNAABCB11MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 920 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117362385-A | Crystal form I of imidapril hydrochloride and preparation method thereof | 湖南九典制药股份有限公司 | 2024-01-09 | — | — | CN | claimed |
| US-20230114308-A1 | Flux-Compatible Epoxy-Anhydride Adhesives Compositions for Low-Gap Underfill Applications | HENKEL AG & CO KGAA (DE) | 2023-04-13 | — | — | US | claimed |
| CN-113024632-B | Preparation method of imidapril hydrochloride | 山东中健康桥制药有限公司 | 2023-03-28 | — | — | CN | claimed |
| CN-110927278-B | Improved method for separating imidapril hydrochloride related substances | 湖南九典制药股份有限公司 | 2022-07-01 | — | — | CN | claimed |
| CN-110927279-B | Method for separating imidapril hydrochloride related substances | 湖南九典制药股份有限公司 | 2022-06-28 | — | — | CN | claimed |
| CN-113024632-A | Preparation method of imidapril hydrochloride | 山东中健康桥制药有限公司 | 2021-06-25 | — | — | CN | claimed |
| CN-111329840-B | Imidapril hydrochloride tablet and preparation method thereof | 北京阳光诺和药物研究股份有限公司 | 2021-02-09 | — | — | CN | claimed |
| CN-111329840-A | Imidapril hydrochloride tablet and preparation method thereof | 北京阳光诺和药物研究股份有限公司 | 2020-06-26 | — | — | CN | claimed |
| CN-111253315-A | Imidapril hydrochloride organic impurity and preparation method thereof | 北京阳光诺和药物研究有限公司 | 2020-06-09 | — | — | CN | claimed |
| CN-110927279-A | Method for separating imidapril hydrochloride related substances | 湖南九典制药股份有限公司 | 2020-03-27 | — | — | CN | claimed |
| EP-1553091-A1 | HETEROAROMATIC PENTACYCLIC COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-07-13 | — | — | EP | claimed |
| EP-1533292-A1 | DIBENZYLAMINE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-05-25 | — | — | EP | claimed |
| US-20050075367-A1 | Ester compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-04-07 | — | — | US | claimed |
| US-20050059810-A1 | Dibenzylamine compound and medicinal use thereof | JAPAN TOBACCO INC | 2005-03-17 | — | — | US | claimed |
| US-20050043391-A1 | Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome | NAVITAS PHARMA, INC. CORPORATION | 2005-02-24 | — | — | US | claimed |
| WO-2005009446-A1 | COMBINATION THERAPIES FOR TREATMENT OF HYPERTENSION AND COMPLICATIONS IN PATIENTS WITH DIABETES OR METABOLIC SYNDROME | COTHERIX, INC. (US) | 2005-02-03 | — | — | WO | claimed |
| EP-1479666-A1 | ESTER COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-11-24 | — | — | EP | claimed |
| US-20040122042-A1 | Drugs containing chymase inhibitor and ace inhibitors as the active ingredients | TEIJIN PHARMA LIMITED (JP) | 2004-06-24 | — | — | US | claimed |
| EP-1419785-A1 | DRUGS CONTAINING CHYMASE INHIBITOR AND ACE INHIBITOR AS THE ACTIVE INGREDIENTS | TEIJIN LIMITED (JP) | 2004-05-19 | — | — | EP | claimed |
| US-5603961-A | COMPRISING MICROREGIONS OF FIRST BIODEGRADABLE POLYMER HAVING ACTIVE INGREDIENT RETAINED THEREIN DISTRIBUTED IN CONTINUOUS REGION OF SECOND BIODEGRADABLE POLYMER | TANABE SEIYAKU CO., LTD. (JP) | 1997-02-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059810-A1 | Dibenzylamine compound and medicinal use thereof | CETP, CES1, APOB | ACE 1101/4885LMNA 1556/4885ABCB11 39/4885 |
| US-20050075367-A1 | Ester compound and medicinal use thereof | LIPC, CES1, MTTP | ACE 1479/4885LMNA 2248/4885ABCB11 410/4885 |
| US-20040122042-A1 | Drugs containing chymase inhibitor and ace inhibitors as the active ingredients | ACE, AGT, REN | ACE 1/4885LMNA 430/4885ABCB11 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.